Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

NEXT STORY
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
PREV STORY
Global $32.67 Billion Bioethanol Yeast Market to 2028: Cleaning & Disinfection Segment Projected to Register the Fastest CAGR Over Forecast Period
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

BEVERLY, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

HUD REPORT TO CONGRESS: HOMELESSNESS INCREASED FOR FOURTH YEAR IN A ROW; RACIAL INEQUITIES PERSIST

author_avatar
NASDAQ Market News

Growth Opportunities for IoT-enabled medical devices for Infectious disease management

author_avatar
NASDAQ Market News